anised monoclonal antibody (OPN-305) to a key
toll-like receptor (TLR) target, has demonstrated efficacy in a number of
animal models and will start pivotal clinical trials in 2010.
Florent Gros, managing director, Novartis Venture Fund added, "We are
delighted to be working with Opsona Therapeutics and the other investors to
assist Opsona in progressing the company's highly innovative technology and
approaches towards the clinic. The innate immune system represents a new
frontier in targeting inflammatory diseases, and the caliber of the investors
in this funding round is a demonstration of Opsona's expertise and
capabilities in this highly promising field.'
Opsona has also announced the opening of a new facility in Switzerland.
The Swiss laboratory will carry out pivotal assay development and biochemical
work for new projects and therapeutics recently acquired by Opsona to expand
its pipeline of immunomodulators. The expertise that it intends to grow in
Switzerland will complement the existing team and activity in Dublin.
Dr Cormac Kilty, Chairman of Opsona and past Chairman of the Irish
Bioindustry Association explains "This is major achievement for any
biotechnology company in the current economic climate. Opsona's R&D shows
that emerging Irish companies can reach international recognition in
Notes to Editors:
About Opsona Therapeutics
Opsona is a drug development company, focused on novel therapeutic and
preventative approaches to autoimmune and inflammatory diseases. The company
was founded in 2004 with three of Trinity College Dublin's respected
Immunologists (Professors Luke O'Neill, Kingston Mills and Dermot Kelleher).
The company is specifically interested in drugs which modulate the innate
immune system and its signalling, specifically Toll-Like Receptors (TLR).
Opsona has a pipeline of therapeutics in advanced pre-clini
Page: 1 2 3 4 Related biology technology :1
|SOURCE Opsona Therapeutics Ltd|
Copyright©2009 PR Newswire.
All rights reserved
. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA2
. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review3
. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation4
. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway5
. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 20076
. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer7
. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials8
. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination9
. Amsterdam Molecular Therapeutics Reports Half Year Results 200710
. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member11
. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug